Ozempic and Wegovy in Canada — What Ottawa Patients Need to Know
Semaglutide medications have transformed the treatment of type 2 diabetes and obesity — but supply shortages, insurance confusion, and conflicting media coverage have left many Ottawa patients with more questions than answers. Here is what your pharmacist wants you to know.
What Is Semaglutide? (Ozempic vs. Wegovy)
Semaglutide is the active ingredient in both Ozempic and Wegovy — two brand-name medications from the same pharmaceutical company that are formulated at different doses and approved for different indications. Understanding the distinction is important, especially given how frequently these names are used interchangeably in media coverage.
Semaglutide belongs to a class of drugs called GLP-1 receptor agonists (GLP-1 RAs). GLP-1 is a naturally occurring hormone released after eating that stimulates insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite signals in the brain. By mimicking and amplifying these effects, semaglutide medications improve blood sugar control and, at higher doses, produce significant weight loss.
The Ozempic Supply Shortage in Canada
Canada has experienced significant and ongoing supply constraints with Ozempic since 2022, driven by unprecedented global demand that far outpaced the manufacturer's production capacity. The shortage has disproportionately affected patients with type 2 diabetes who rely on Ozempic as part of their established treatment regimen — not as a weight-loss drug.
Health Canada has issued guidance encouraging physicians to prioritize prescribing for type 2 diabetes patients over off-label weight-loss use when supply is constrained. However, shortages remain unpredictable and vary by pen size (dose). At Longfields Pharmacy, we actively monitor supply levels and will contact you proactively if your pen size is affected. We can also work with your physician to explore therapeutic alternatives if needed.
For patients who cannot reliably access Ozempic or Wegovy due to supply issues or cost, compounding pharmacy alternatives are available — more on that below.
Cost and Drug Coverage in Ontario
The cost and coverage picture for semaglutide medications in Ontario is complex and depends heavily on your insurance situation:
- Ozempic is listed on the Ontario Drug Benefit (ODB) formulary for the treatment of adult patients who are eligible with type 2 diabetes when adequate glycemic control is not achieved on the maximum tolerated dose of metformin or where metformin is contraindicated or inappropriate, it is free or low-cost for those on social assistance, ODSP, or 65+ with a valid ODB card.
- Wegovy is NOT currently listed on the ODB formulary, meaning it is not covered for most Ontario residents without private insurance.
- Many private insurance plans cover Ozempic for type 2 diabetes but require step therapy (trying other medications first). Wegovy coverage varies significantly by plan.
- Without insurance, Ozempic costs approximately $270 per month in Canada, depending on the dose.
- Some patients use manufacturer programs (like the Ozempic Patient Assistance Program) for cost support — ask your pharmacist if you qualify.
At Longfields Pharmacy, we can run a benefits check for you and help navigate prior authorization processes with your insurance company when required. We will also review your full medication list to ensure semaglutide is appropriate given your other medications and health conditions.
Side Effects — What Patients Actually Experience
Semaglutide medications are generally well-tolerated, but gastrointestinal side effects are common, particularly during dose titration (the gradual dose-increase period). Common side effects include:
- Nausea (most common, especially in the first 4–8 weeks)
- Vomiting and diarrhea
- Constipation
- Reduced appetite (this is partly the intended effect)
- Injection site reactions (redness, irritation)
- Fatigue and headache during initiation
More serious but rare side effects include pancreatitis, gallbladder disease, and a theoretical risk of thyroid C-cell tumours (seen in rodent studies — relevance to humans is unclear but Ozempic and Wegovy are contraindicated in patients with a personal or family history of medullary thyroid carcinoma). These medications are also contraindicated in pregnancy.
A key side effect patients are often not warned about is the loss of muscle mass alongside fat mass during rapid weight loss. Without adequate protein intake and resistance exercise, significant muscle can be lost. Your pharmacist can provide guidance on nutritional strategies to preserve muscle while on semaglutide therapy.
Who Qualifies — and Who Should Not Take Semaglutide?
Ozempic is approved for adults with type 2 diabetes. Wegovy is approved for adults with:
- BMI of 30 kg/m² or greater (obesity), OR
- BMI of 27 kg/m² or greater with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, or cardiovascular disease)
Semaglutide is NOT appropriate for patients with:
- Type 1 diabetes
- Personal or family history of medullary thyroid carcinoma or MEN2 syndrome
- Pregnancy or breastfeeding
- Severe gastrointestinal disease (gastroparesis, severe inflammatory bowel disease)
- Previous serious hypersensitivity reaction to semaglutide